{"id":908471,"date":"2026-09-28T10:50:57","date_gmt":"2026-09-28T10:50:57","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/908471\/"},"modified":"2026-09-28T10:50:57","modified_gmt":"2026-09-28T10:50:57","slug":"not-a-miracle-drug-glp-1-meds-not-effective-without-plan-exercise","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/908471\/","title":{"rendered":"&#8216;Not a miracle drug&#8217;: GLP-1 meds not effective without plan, exercise"},"content":{"rendered":"<p>Alan Zellner admittedly expressed some concerns about taking an unfamiliar medication.<\/p>\n<p>However, faced with rising blood pressure and an expanding waistline, the 76-year-old Wilkes-Barre resident followed the advice of his doctors and began taking Ozempic to drop some pounds.<\/p>\n<p>A former standout wrestler and later coach at Wilkes University, Zellner\u2019s weight ballooned to 360 pounds following his retirement.<\/p>\n<p>Zellner started taking the glucagon-like peptide-1 (GLP-1) receptor agonist about three years ago and witnessed his weight drop to 212 pounds when he stepped on the scale Wednesday. He described the medicine as a \u201cvery small part\u201d of his weight loss journey and program.<\/p>\n<p>\u201cChanging my lifestyle, changing my diet and planning meals, and getting more exercise by walking the dog four times a day \u2014 all those things went into losing 150 pounds,\u201d Zellner said.<\/p>\n<p>GLP-1 agonists \u2014\u00a0 a class of medications used to treat Type 2 diabetes mellitus and obesity \u2014 lower serum glucose levels and manage metabolism in patients, according to the National Library of Medicine. Originally developed for the management of Type 2 diabetes, GLP-1s emerged as a highly effective treatment for obesity.<\/p>\n<p>Interest in GLP-1-based prescriptions for people without diabetes rose an estimated 700% from 2019 to 2023, raising concerns about side effects, long-term outcomes and unregulated products, NLM officials said.<\/p>\n<p>Locally, Tom DePietro, owner of DePietro\u2019s Pharmacy in Dunmore, observed a 220% increase of GLP-1 prescriptions for weight loss from January to August.<\/p>\n<p>\u201cPatients finally have access to a solution for a problem in such demand and then you couple it with the fact that now you have somewhat of an affordable pathway to a medication that\u2019s highly effective to treat or assist the treatment of the disease,\u201d he said. \u201cMedicare patients typically never had access to weight-loss medications. Starting in July, Medicare launched a GLP bridge program which gave patients on Medicare Part D for drug plans an option to become covered if they met weight guidelines and\/or other conditions. Since July, we\u2019ve seen about 100 patients access that program.<\/p>\n<p>\u201cI think the demand is going to continue to increase. That program alone will cause a tremendous increase of growth. If the patients qualify, they pay $50 per month so even our Medicare senior patients find that affordable. Typically, it\u2019s over $1,300 a month.\u201d<\/p>\n<p>Pharmaceutical manufacturers also realized many insurance companies won\u2019t cover the drugs so they\u2019ve launched very competitive, monthly co-pay offerings for consumers to buy it out-of-pocket, DePietro said.<\/p>\n<p>\u201cWe\u2019re seeing patients pay anywhere from $140 to $499 a month, out of pocket,\u201d he said. \u201cTheir argument was if I could afford it, and my healthcare is not covering it, and it\u2019s going to add years to my life, decrease my blood pressure and help my overall day-to-day (health), I think people look at the cost of medications now differently, especially for this type of condition. A lot of people want to lose weight and tried very hard, and now they\u2019re seeing other people have the results, which I think is leading to this year-over-year increase in demand.\u201d<\/p>\n<p>Wegovy and Zepbound are the two main GLP-1 medications on the market, and the introduction of a tablet version of Wegovy spurred even more interest in the medication, DePietro said.<\/p>\n<p>\u201cIt helped increase the demand for GLPs because a subset of patients were unwilling to inject a needle,\u201d he said. \u201cWhen that tablet was launched, those people kind of came off the sideline.\u201d<\/p>\n<p>DePietro noted Ozempic and Wegovy are exactly the same drug, but there is a different name on the box.<\/p>\n<p>\u201cOne box is for diabetics and one box is for weight loss,\u201d he said. \u201cThe Ozempic box is intended to be used by patients whose doctor said they have diabetes. The other box was intended for people who said they want to lose weight. Early on, people realized the diabetic drug was causing weight loss. They had access to Ozempic and that\u2019s what really caused the craze of, \u2018This medication that treats diabetes is also causing tremendous weight loss, we should make a box and call it something else and sell it for weight loss.\u2019\u2009\u201d<\/p>\n<p>Additionally, Mounjaro and Zepbound are also the same medication with two different names on the boxes \u2014 one for diabetes (Mounjaro) and one for weight loss, DePietro said.<\/p>\n<p>\u201cThose four products are dominating the market,\u201d he said.<\/p>\n<p>Dr. Christopher Still, director of Geisinger\u2019s Center for Obesity and Metabolic Research, said the GLP medications serve many purposes.<\/p>\n<p>\u201cThe GLP-1s really transformed not only obesity treatment, but cardiometabolic care,\u201d he said. \u201cThey\u2019ve been shown to be decreasing cardiovascular risk; it\u2019s indicated now for fatty liver disease and obstructive sleep apnea. There have been studies looking at really any chronic disease of inflammation like psoriasis and asthma, and even substance use disorders. It\u2019s really been a game changer for cardiometabolic disease overall.\u201d<\/p>\n<p>The GLP-1s have also proven to be more effective for weight loss than previous drugs, Still added.<\/p>\n<p>\u201cThey\u2019re safe and effective and before the injectables, the GLP-1s, if you look historically at anti-obesity medication, the average weight loss was about 5 to 7, maybe 8% weight loss,\u201d he said. \u201cNow, with the newer medications, we\u2019re getting 21% to 22% weight loss and even more in the newer medications that are coming out in the near future. There\u2019s probably 15 medications in development so I would bet, in the next three to five years, you\u2019re going to see a significant increase in the number of medications in the cardiometabolic space.\u201d<\/p>\n<p>Most side effects from GLP-1 medications are related to the gastrointestinal tract \u2014 nausea, constipation, abdominal discomfort, increase in reflux, Still said.<\/p>\n<p>\u201cOne important point about these medications is they\u2019re very effective, but you need to be on them long term,\u201d he said. \u201cIf you look at any of the studies, when you stop the medication abruptly, two-thirds of patients will gain back their weight within one year and it\u2019s really no fault of the patient.\u201d<\/p>\n<p>Maintaining a high-quality diet featuring ample protein, fruits and vegetables, and getting proper exercise, including resistance training, are also important when taking the GLP medications, Still said.<\/p>\n<p>With many insurances not covering the medications, Still also fears consumers will try to acquire them from compounding pharmacies, which are not regulated by the FDA.<\/p>\n<p>\u201cIt\u2019s a big concern because we just don\u2019t know what the active ingredient is in those medications,\u201d he said.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Alan Zellner of Wilkes-Barre on Wednesday, Sept. 23, 2026. JASON...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP-0927-1.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Alan Zellner of Wilkes-Barre on Wednesday, Sept. 23, 2026. JASON ARDAN \/ STAFF PHOTOGRAPHER\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Alan Zellner of Wilkes-Barre on Wednesday, Sept. 23, 2026. JASON...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP-0927-5.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Alan Zellner of Wilkes-Barre on Wednesday, Sept. 23, 2026. JASON ARDAN \/ STAFF PHOTOGRAPHER\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Alan Zellner of Wilkes-Barre speaks on his experience with Ozempic...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP-0927-2.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Alan Zellner of Wilkes-Barre speaks on his experience with Ozempic on Wednesday, Sept. 23, 2026. JASON ARDAN \/ STAFF PHOTOGRAPHER\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Pharmacist Sarah Ferry holds up A package of GLP-1 medication...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP1-0925-02.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Pharmacist Sarah Ferry holds up A package of GLP-1 medication at DePietro\u2019s Pharmacy in Dunmore Thursday, September 24, 2026. (SEAN MCKEAG \/ STAFF PHOTOGRAPHER)\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Pharmacist Sarah Ferry holds up A package of GLP-1 medication...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP1-0925-03.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Pharmacist Sarah Ferry holds up A package of GLP-1 medication at DePietro\u2019s Pharmacy in Dunmore Thursday, September 24, 2026. (SEAN MCKEAG \/ STAFF PHOTOGRAPHER)\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"GLP-1 medication is shown on the counter at DePietro\u2019s Pharmacy...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP1-0925-04.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>GLP-1 medication is shown on the counter at DePietro\u2019s Pharmacy in Dunmore Thursday, September 24, 2026. (SEAN MCKEAG \/ STAFF PHOTOGRAPHER)\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"Pharmacist Sarah Ferry holds up packages of the GLP-1 medication...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/STT-L-GLP1-0925-01.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>Pharmacist Sarah Ferry holds up packages of the GLP-1 medication at DePietro\u2019s Pharmacy in Dunmore Thursday, September 24, 2026. (SEAN MCKEAG \/ STAFF PHOTOGRAPHER)\n<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"This photograph taken on February 23, 2023, in Paris, shows...\" class=\"lazyload size-article_inline\" data- src=\"https:\/\/www.thetimes-tribune.com\/wp-content\/uploads\/2026\/09\/202603151705MCT_____PHOTO____US-NEWS-MED-CMP-PENN-GLP-1-STUDY-FILEPIC-GET.jpg?w=620\"  bad-src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\"\/><\/p>\n<p>This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication Ozempic, made by Danish pharmaceutical company Novo Nordisk. (Joel Saget\/GETTY IMAGES EUROPE\/TNS)\n<\/p>\n<p>Show Caption<\/p>\n<p>1 of 8<\/p>\n<p>Alan Zellner of Wilkes-Barre on Wednesday, Sept. 23, 2026. JASON ARDAN \/ STAFF PHOTOGRAPHER\n<\/p>\n<p><a href=\"#\" class=\"icon-enlarge mng-gallery-fullscreen-expand\" aria-label=\"Expand fullscreen slideshow\">Expand<\/a><\/p>\n<p>Dr. Essam Almeky, a primary care physician and director of the medical weight loss program at Commonwealth Health in Kingston, emphasized that GLP-1 medications alone won\u2019t help patients lose weight, but they can be an effective tool in the process.<\/p>\n<p>\u201cI have patients that come here and ask for magic, basically,\u201d he said. \u201cI tell them I don\u2019t have magic, but you do. If the patient follows the diet plan I give them and the muscle exercises, I have great results. But by itself, it doesn\u2019t work. I\u00a0have patients who took the shot and didn\u2019t lose any weight. They would just eat their way around it and then they complain about nausea because if you overeat, you have more nausea with these medications. Then they ask for nausea medication, and we get into a vicious circle with that.\u201d<\/p>\n<p>The medications can also decrease heart diseases and stroke by 30%, Almeky said.<\/p>\n<p>For patients looking to lose large amounts of weight, Almeky typically starts them on other medications before transitioning to the GLP-1s.<\/p>\n<p>\u201cOnce you reach the highest dose, you\u2019re done with weight loss with the GLP-1,\u201d he said. \u201cThey think it\u2019s going to work forever and they\u2019re going to keep losing the weight. It doesn\u2019t work like that. I have a lot of success when we taper them down. When they taper down with a practitioner to help with the calories and all of that, then they do very well and keep the weight off.\u201d<\/p>\n<p>Microdosing \u2014 staying on the lowest dose forever or for years after \u2014 is also a common practice, Almeky said<\/p>\n<p>\u201cStaying with the low dose will actually help them build their new lifestyle,\u201d he said. \u201cIt keeps them in check. In the studies, it shows that GLP-1s help with maintenance of the weight loss.\u201d<\/p>\n<p>Zellner relied on his sports background to craft a weight-loss plan, including keeping a written log of all his meals and including his entire family in the process.<\/p>\n<p>\u201cI went on one of my wrestling diets that I used to recommend to my team,\u201d he said. \u201cI started to lose weight and then Dr. Almeky thought it would be a little bit faster if I started taking this medicine. Initially, he asked me to take a .25-milligram dose and then moved up to the .5 dose. Then, after six weeks, I went up to the 1.0 dose and that was making me sick. I was nauseous, my heart rate was high and my blood pressure went low, so we cut back to the .5 and I\u2019ve basically been fine since then. I was not a big fan of it but his nephew wrestled for me, so I started to take the medicine as a favor.\u201d<\/p>\n<p>While Zellner remains on a .5-milligram dose of Ozempic, he firmly believes lifestyle choices play a bigger role in keeping the weight off.<\/p>\n<p>\u201cIt\u2019s more with doing the exercise, planning your meals and increasing your water intake,\u201d he said. \u201cAfter I retired from coaching, my schedule kind of went all over. I was eating whenever I got a chance and eating late at night. When (Almeky) said I needed to lose weight, I knew I needed to get back on a legitimate schedule. I needed to cut the junk food and stop eating at the fast-food places. That discipline is the most important.\u201d<\/p>\n<p>Zellner feels the GLP-1 medication, in conjunction with a healthy diet and regular exercise, helped improve his overall health.<\/p>\n<p>\u201cMy sleep apnea has subsided, my blood pressure is better and my cholesterol is better,\u201d he said. \u201cIt\u2019s not a miracle drug, but the program has been effective.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Alan Zellner admittedly expressed some concerns about taking an unfamiliar medication. However, faced with rising blood pressure and&hellip;\n","protected":false},"author":2,"featured_media":908472,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,78528,2289,78529,490,44,12274,79800,42866],"class_list":["post-908471","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-au","tag-australia","tag-health","tag-lackawanna-county","tag-local-news","tag-luzerne-county","tag-medication","tag-news","tag-pennsylvania","tag-top-stories-stt","tag-wilkes-barre"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/908471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=908471"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/908471\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/908472"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=908471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=908471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=908471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}